Preview

Комплексные проблемы сердечно-сосудистых заболеваний

Расширенный поиск

ОСОБЕННОСТИ ТЕЧЕНИЯ И СТРАТИФИКАЦИИ РИСКА ОСЛОЖНЕНИЙ ОСТРОГО КОРОНАРНОГО СИНДРОМА В СОЧЕТАНИИ С ПОЧЕЧНОЙ ДИСФУНКЦИЕЙ И РАЗЛИЧНОЙ СТРАТЕГИЕЙ ЛЕЧЕНИЯ (обзор литературы)

https://doi.org/10.17802/2306-1278-2015-3-68-78

Полный текст:

Аннотация

В данном обзоре приводятся доказательства актуальности поиска новых факторов, ассоциированных с неблагоприятным течением острого коронарного синдрома. Одним из таких факторов является почечная дисфункция, прогностическую роль которой сложно переоценить. В последние годы появилось много, зачастую противоречивой, информации о новых биохимических и генетических маркерах повреждения почек и почечной дисфункции. Это диктует необходимость в систематизации и пересмотре существующих представлений о данной проблеме.

Об авторе

Михаил Валерьевич Зыков
Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний»; Муниципальное бюджетное учреждение здравоохранения г. Сочи «Городская больница № 4»
Россия

Кемерово;

354000, г. Сочи, ул. Дагомысская, д. 42



Список литературы

1. Самородская И. В. Острые формы ишемической болезни сердца: необходимость решения проблемы сопоставимости данных о распространенности и летальности. Болезни сердца и сосудов. 2010; 1: 25–28. Samorodskaya I. V. Ostrye formy ishemicheskoy bolezni serdtsa: neobkhodimost’ resheniya problemy sopostavimosti dannykh o rasprostranennosti i letal’nosti. Bolezni serdtsa i sosudov. 2010; 1: 25–28. [In Russ].

2. Информационный бюллетень Всемирной организации здравоохранения № 310 (май 2014 года). 10 ведущих причин смерти в мире [Интернет]. Режим доступа: http://www.who.int/mediacentre/factsheets/fs310/ru/ (дата обращения: 03.04.2015).

3. Informacionnyj bjulleten′ Vsemirnoj organizacii zdravoohranenija № 310 (maj 2014 goda). 10 vedushhih prichin smerti v mire [Internet]. Режим доступа: http://www.who.int/mediacentre/factsheets/fs310/ru/ (data obrashhenija: 03.04.2015). [In Russ].

4. Lu H. T., Nordin R. B. Ethnic differences in the occurrence of acute coronary syndrome: results of the Malaysian National Cardiovascular Disease (NCVD) Database Registry (March 2006 – February 2010). BMC Cardiovascular Disorders. 2013; 13: 97. doi:10.1186/1471-2261-13-97.

5. Оганов Р. Г., Фомина И. Г. Болезни сердца: руководство для врачей. М; 2006. Oganov R. G., Fomina I. G. Bolezni serdtsa: rukovodstvo dlya vrachey. M; 2006. [In Russ].

6. Ощепкова Е. В., Ефремова Ю. Е., Карпов Ю. А. Заболеваемость и смертность от инфаркта миокарда в Российской Федерации в 2000–2011 гг. Терапевтический архив. 2013; 4: 4–10. Oshchepkova E. V., Efremova Yu. E., Karpov Yu. A. Myocardial infarction morbidity and mortality in the Russian Federation in 2000–2011. Terapevticheskiy arkhiv. 2013; 4: 4–10. [In Russ].

7. Mandelzweig L., Battler A., Boyko V., Bueno H., Danchin N., Filippatos G. et al. The second Euro Heart Survey on acute coronary syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. European Heart Journal. 2006; 27: 2285–2293. doi:10.1093/eurheartj/ehl1962006.

8. Posnenkova O. M., Kiselev A. R., Popova Yu. V., Gridneva V. I., Prokhorov M. D., Dovgalevsky P. Ya. et al. Impact of patient-related and treatment-related factors on in-hospital mortality of patients with ST-elevation myocardial infarction: Data of Russian Acute Coronary Syndrome Registry. Cor et Vasa. 2014; 56: e217–227.

9. Ощепкова Е. В., Дмитриев В. А., Гриднев В. И., Довга­левский П. Я. Организация медицинской помощи больным с острым коронарным синдромом без подъема сегмента ST в региональных сосудистых центрах и первичных сосудистых отделениях в 2009–2012 гг. (по данным регистра ОКС). Терапевтический архив. 2013; 12: 4–8. Oshchepkova E. V., Dmitriev V. A., Gridnev V. I., Dovgalevsky P. Ya. Organization of medical care for patients with non-ST-segment elevation acute coronary syndrome in regional vascular centers and primary vascular units in 2009–2012 (according to the data of the ACS register). Terapevticheskiy arkhiv. 2013; 12: 4–8. [In Russ].

10. Hamm C. W., Bassand J.-P., Agewall S., Bax J., Boersma E., Bueno H. et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 2011; 32 (23): 2999–3054. doi: 10.1093/eurheartj/ehr236.

11. Кохан Е. П. Нестабильная стенокардия: современный подход к активной тактике лечения. Хирургическая реваскуляризация или чрескожная транслюминальная коронарная ангиопластика. Ангиология и сосудистая хирургия. 2000; 2: 100–105. Kokhan E. P. Nestabil’naya stenokardiya: sovremennyy podkhod k aktivnoy taktike lecheniya. Khirurgicheskaya revaskulyarizatsiya ili chreskozhnaya translyuminal’naya koronarnaya angioplastika. Angiologiya i sosudistaya khirurgiya. 2000; 2: 100–105. [InRuss].

12. Mohareb M., Goodman S. G., Yan R. T., Bhatt D. L., Elbarouni B., DeYoung J. P. et al. Treatment and outcomes of non-ST elevation acute coronary syndromes in relation to burden of pre-existing vascular disease. Internat. J. Cardiol. 2013; 168 (3): 2720–2725.

13. Donataccio M. P., Puymirat E., Vassanelli C., Blanchard D., le Breton H., Perier M. C. et al. Presentation and revascularization patterns of patients admitted for acute coronary syndromes in France between 2004 and 2008 (from the National Observational Study of Diagnostic and Interventional Cardiac Catheterization [ONACI]). Am. J. Cardiol. 2014; 113(2): 243–248. doi: 10.1016/j.amjcard.2013.09.014.

14. Subherwal S., Bhatt D. L., Li S., Wang T. Y., Laine T., Karen P. A. et al. Polyvascular disease and long-term cardiovascular outcomesin older patients with non–ST-segment elevation myocardial infarction. Circ. Cardiovasc. Qual. Outcomes. 2012; 5 (4): 541–549. doi: 10.1161/CIRCOUTCOMES.111.964379.

15. Hoshino H., Itoh Y., Yamada S., SuzukiN. Prevalence and clinical features of asymptomatic peripheral artery disease in Japanese stroke patients. J. Stroke Cerebrovasc. Dis. 2013; 22 (3): 255–259. doi: 10.1016/j.jstrokecerebrovasdis.2011.08.011.

16. Kablak-Ziembicka A., Tracz W., Przewlocki T., Pieniazek P., Sokolowski A., Konieczynska M. Association of increased carotid intima-media thickness with the extent of coronary artery disease. Heart. 2004; 90 (11): 1286–1290. doi: 10.1136/hrt.2003.025080.

17. Windecker S., Kolh P., Alfonso F., Collet J.-P., Cremer J., Falk V. 2014 ESC/EACTS Guidelines on myocardial revascularization. The task gorce on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2014; 35; 2541–2619. doi:10.1093/eurheartj/ehu278.

18. Bangalore S., Pursnani S., Kumar S., Bagos P. G. Percutaneous coronary intervention vs. optimal medical therapy for prevention of spontaneous myocardial infarction in subjects with stable ischemic heart disease. Circulation. 2013; 127 (7): 769–781. doi: 10.1161/CIRCULATIONAHA.112.131961.

19. O’Donoghue M., Boden W. E., Braunwald E., Cannon C. P., Clayton T. C., de Winter R. J. et al. Early invasive vs. conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2008; 300(1): 71–80. doi:10.1001/jama.300.1.71.

20. Antman Е. M., Cohen M., Bernink P. J. L. M., McCabe C. H., Horacek T., Papuchis G. et al. Тhe TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA. 2000; 284 (7): 835–842.

21. Boersma Е., PieperK. S., Steyerberg E. W., Wilcox R. G., Chang W.-C., Lee K. L. et al. Predictors of out-come in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation. 2000; 101: 2557–2567. doi: 10.1161/01.CIR.101.22.2557.

22. Morrow D. A., Antman E. M., Charlesworth A., Cairns R., Murphy S. A., de Lemos J. A. et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000; 102 (17): 2031–2037. doi: 10.1161/01.CIR.102.17.2031.

23. Halkin A., Singh M., Nikolsky E., Grines C. L., Tcheng J. E., Garcia E. et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: The CADILLAC Risk Score. J. Amer. Coll Cardiol. 2005; 45 (9): 1397–1405.

24. Fox К. А. A., Dabbous О. Н., Goldberg R. J., Pieper K. S., Eagle K. A., de Werf F. V. et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). Br. Med. J. 2006; 333: 1091–1094. doi: http://dx.doi.org/10.1136/bmj.38985.646481.55.

25. D’Ascenzo F., Biondi-Zoccai G., Moretti C., Bollati M., Omedè P., Sciuto F. et al. TIMI, GRACE and alternative risk scores in acute coronary syndromes: Ameta-analysis of 40 derivation studies on 216,552 patients and of 42 validation studies on 31,625 patients. Contemporary Clinical Trials. 2012: 1–8. doi: 10.1016/j.cct.2012.01.001.

26. Bawamia B., Mehran R., Qiu W., Kunadian V. Risk scores in acute coronary syndrome and percutaneous coronary intervention: a review. Am. Heart J. 2013; 165 (4): 441–450. doi: 10.1016/j.ahj.2012.12.020.

27. Eagle K. A., Lim M. J., Dabbous O. H., Pieper K. S., Goldberg R. J., Van de Werf F. et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004; 291 (22): 2727–2733.

28. Palmerini T., Genereux P., Caixeta A., Cristea E., Lansky A., Mehran R. et al. A new score for risk stratification of patients with acute coronary syndromes undergoing percutaneous coronary intervention: The ACUITY-PCI (Acute Catheterization and Urgent Intervention Triage Strategy-Percutaneous Coronary Intervention) Risk Score. JACC. 2012; 5 (11): 1108–1116. doi: 10.1016/j.jcin.2012.07.011.

29. Lev E. I., Kornowski R., Vaknin-Assa H. Porter A., Teplitsky I., I. Ben-Dor et al. Comparison of the predictive value of four different risk scores for outcomes of patients with STelevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Am. J. Cardiol. 2008; 102 (1): 6–11.

30. Abu-Assi E., Ferreira-González I., Ribera A., Marsal J. R., Cascant P., Heras M. et al. Do GRACE (Global Registry of Acute Coronary Events) risk scores still maintain their performance for predicting mortality in the era of contemporary management of acute coronary syndromes? Am. Heart J. 2010; 160 (5): 826–834. doi: 10.1016/j.ahj.2010.06.053.

31. Méndez-Eirín E., Flores-Ríos X., García-López F., Pérez-Pérez A. J., Estévez-Loureiro R., Piñón-Esteban P. et al. Comparison of the prognostic predictive value of the TIMI, PAMI, CADILLAC, and GRACE risk scores in STEACS undergoing primary or rescue PCI. Rev. Esp. Cardiol. 2012; 65 (3): 227–233. doi: 10.1016/j.recesp.2011.10.019.

32. Kozieradzka A., Kamiński K. A., Maciorkowska D., Olszewska M., Dobrzycki S., Nowak K. et al. GRACE, TIMI, ZWOLLE and CADILLAC risk scores – do they predict 5-year outcomes after ST-elevation myocardial infarction treated invasively? Int. J. Cardiol. 2011; 148 (1): 70–75. doi: 10.1016/j.ijcard.2009.10.026.

33. Khan S. Q., Narayan H., Ng K. H., Dhillon O. S., Kelly D., Quinn P. et al. N-terminal pro-B-type natriuretic peptide complements the GRACE risk score in predicting early and late mortality following acute coronary syndrome. Clin. Sci. (Lond). 2009; 117(1): 31–39. doi: 10.1042/CS20080419.

34. Eggers K. M., Kempf T., Venge P., Wallentin L., Wollert K. C., Lindahl B. Improving long-term risk prediction in patients with acute chest pain: the Global Registry of Acute Coronary Events (GRACE) risk score is enhanced by selected nonnecrosis biomarkers. Am. Heart J. 2010; 160 (1): 88–94. doi: 10.1016/j.ahj.2010.05.002.

35. Meune C., Drexler B., Haaf P., Reichlin T., Reiter M., Meissner J. et al. The GRACE score’s performance in predicting in-hospital and 1-year outcome in the era of high-sensitivity cardiac troponin assays and B-type natriuretic peptide. Heart. 2011; 97(18): 1479–1483. doi: 10.1136/hrt.2010.220988.

36. Brkovic V., Dobric M., Beleslin B., Giga V., Vukcevic V., Stojkovic S. et al. Additive prognostic value of the SYNTAX score over GRACE, TIMI, ZWOLLE, CADILLAC and PAMI risk scores in patients with acute ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention. Int. J. Cardiovasc. Imaging. 2013; 29(6): 1215–1228. doi: 10.1007/s10554-013-0202-1.

37. Fox C. S., Muntner P., Chen A. Y., Alexander K. P., Roe M. T., Cannon C. P. et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation. 2010; 121: 357–365. doi: 10.1161/CIRCULATIONAHA.109.865352.

38. Смирнов А. В., Шилов Е. М., Добронравов В. А., Ка­юков И. Г., Бобкова И. Н., Швецов М. Ю. и др. Национальные рекомендации. Хроническая болезнь почек: основные положения, определение, диагностика, скрининг, подходы к профилактике и лечению. Клиническая нефрология. 2012; 4: 4–26. Smirnov A. V., Shilov E. M., Dobronravov V. A., Kayukov I. G., Bobkova I. N., Shvetsov M. Yu. i dr. Natsional’nye rekomendatsii. Khronicheskaya bolezn’ pochek: osnovnye polozheniya, opredelenie, diagnostika, skrininig, podkhody k profilaktike i lecheniyu. Klinicheskaya nefrologiya. 2012; 4: 4–26.

39. GibsonC. M., DumaineR. L., GelfandE.V., Murphy S.A., Morrow D. A., Wiviott S. D. et al. Association of glomerular filtration rate on presentation with subsequent mortality in nonST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. Eur. Heart. J. 2004; 25(22): 1998–2005.

40. Baber U., Stone G. W., Weisz G., Moreno P., Dangas G., Maehara A. et al. Coronary plaque composition, morphology, and outcomes in patients with and without chronic kidney disease presenting with acute coronary syndromes. JACC Cardiovasc. Imaging. 2012; 5 (3 Suppl): 53–61. doi: 10.1016/j.jcmg.2011.12.008.

41. Kuitunen A., Vento A., Suojaranta-Ylinen R., Pettilä V. Acute renal failure after cardiac surgery: evaluation of the RIFLE classification. Ann. Thorac. Surg. 2006; 81 (2): 542–546.

42. Stevens L.A., Coresh J., Greene T., LeveyA. S. Assessing kidney function – measured and estimated glomerular filtration rate. N. Engl. J. Med. 2006; 354: 2473–2483. doi: 10.1056/NEJMra054415.

43. Medi C., Montalescot G., Budaj A., Fox K. A., LópezSendón J., FitzGerald G. et al. Reperfusion in patients with renal dysfunction after presentation with ST-segment elevation or left bundle branch block: GRACE (Global Registry of Acute Coronary Events). JACC Cardiovasc. Interv. 2009; 2(1): 26–33. doi: 10.1016/j.jcin.2008.09.010.

44. Koganei H., Kasanuki H., Ogawa H., Tsurumi Y. Association of glomerular filtration rate with unsuccessful primary percutaneous coronary intervention and subsequent mortality in patients with acute myocardial infarction: from the HIJAMI registry. Circ. J. 2008; 72(2): 179–185.

45. Hemmelgarn B. R., Southern D., Culleton B. F., Mitchell L. B., Knudtson M. L., Ghali W. A. et al. Survival after coronary revascularization among patients with kidney disease. Circulation. 2004; 110(14): 1890–1895.

46. Вельков В. В. NGAL – «ренальный тропонин»: ранний маркер острого повреждения почек. Пущино; 2011. Vel’kov V. V. NGAL – «renal’nyy troponin»: ranniy marker ostrogo povrezhdeniya pochek. Pushchino; 2011. [In Russ].

47. Uchino S. Creatinine. Curr. Opin. Cri.t Care. 2010; 16 (6): 562–567. doi: 10.1097/MCC.0b013e32833ea7f3.

48. Shen S. J., Hu Z. X., Li Q. H., Wang S. M., Song C. J., Wu D. D. et al. Implications of the changes in serum NGAL and CYS-C in patients with chronic kidney disease. Nephrology (Carlton). 2014; 19 (3): 129–135. doi: 10.1111/nep.12203.

49. Vernuccio F., Grutta G., Ferrara F., Novo G., Novo S. Cardiorenal syndrome: the role of new biochemical markers. Recenti. Prog. Med. 2012; 103 (12): 559–563. doi: 10.1701/1206.13356.

50. Schmidt-Ott K. M., Mori K., Li J. Y., Kalandadze A., Cohen D. J., Devarajan P., Barasch J. Dual action of neutrophil gelatinase-associated lipocalin. J. Am. Soc. Nephrol. 2007; 18 (2): 407–413.

51. Шафранская К. С., Кашталап В. В., Баздырев Е. Д., Барбараш О. Л. Возможности диагностики острого повреждения почек с использованием липокалина, ассоциированного с желатиназой нейтрофилов (ngal) в кардиологии (обзор литературы). Сибирский медицинский журнал. 2011; 26 (4): 15–19. Shafranskaya K. S., Kashtalap V. V., Bazdyrev E. D., Barbarash O. L. The possibilities of early acute kidney injury diagnostics using neutrophil gelatinase-associated lipocalin (ngal) in cardiology (review). Sibirskiy meditsinskiy zhurnal. 2011; 26 (4): 15–19. [In Russ].

52. Мензоров М. В., Шутов А. М., Макеева Е. Р., Ми­хайлова Е. В., Парфенова Е. А. Роль липокалина, ассоциированного с желатиназой нейтрофилов, в раннем прогнозировании острого повреждения почек у больных острым коронарным синдромом. Фундаментальные исследования. 2013; (9): 698–702. Menzorov M. V., Shutov A. M., Makeeva E. R., Mikhailova E. V., Parfenova E. A. The role of neutrophil gelatinaseassociated lipocalin for the early prediction of acute kidney injury in patients with acute coronary syndrome. Fundamental research. 2013; (9): 698–702. [In Russ].

53. Seitz S., Rauh M., Gloeckler M., Cesnjevar R., Dittrich S., Koch A. M. Cystatin C and neutrophil gelatinase-associated lipocalin: biomarkers for acute kidney injury after congenital heart surgery. Swiss. Med. Wkly. 2013; 143: w13744. doi: 10.4414/smw.2013.13744.

54. Hirsch R., Dent C., Pfriem H., Allen J., Beekman R. H., Ma Q. et al. NGAL is an early predictive biomarker of contrastinduced nephropathy in children. Pediatr. Nephrol. Pediatr Nephrol. 2007; 22 (12): 2089–2095.

55. Choi K. M., Lee J. S., Kim E. J., Baik S. H., Seo H. S., Choi D. S. et al. Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease. Eur. J. Endocrinol. 2008; 158 (2): 203–207. doi: 10.1530/EJE-07-0633.

56. Zografos T., Haliassos A., Korovesis S., Giazitzoglou E., Voridis E., Katritsis D. Association of neutrophil gelatinaseassociated lipocalin with the severity of coronary artery disease. Am. J. Cardiol. 2009; 104 (7): 917–920. doi: 10.1016/j.amjcard.2009.05.023.

57. Särndahl E., Bergström I., Brodin V. P., Nijm J., Setterud H. L., Jonasson L. Neutrophil activation status in stable coronary artery disease. PLoS ONE. 2007; 2 (10): e1056.

58. Kafkas N., Demponeras C., Zoubouloglou F., Spanou L., Babalis D., Makris K. Serum levels of gelatinase associated lipocalin as indicator of the inflammatory status in coronary artery disease. International Journal of Inflammation. 2012; 2012: 1–8. http://dx.doi.org/10.1155/2012/189797.

59. Lindberg S., Pedersen S. H., Mogelvang R., Jensen J. S., Flyvbjerg A., Galatius S. et al. Prognostic utility of neutrophil gelatinase-associated lipocalin in predicting mortality and

60. cardiovascular events in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. J. Am. Coll. Cardiol. 2012; 60 (4): 339–345. doi: 10.1016/j.jacc.2012.04.017.

61. Daniels L. B., Barrett-Connor E., Clopton P., Laughlin G. A., Ix J. H., Maisel A. S. Plasma neutrophil gelatinaseassociated lipocalin is independently associated with cardiovascular disease and mortality in community-dwelling older adults. J. Am. Coll. Cardiol. 2012; 59 (12): 1101–1109. doi: 10.1016/j.jacc.2011.11.046.

62. Hasegawa M., Ishii J., Kitagawa F., Takahashi K., Hayashi H., Koide S. et al. Urinary neutrophil gelatinaseassociated lipocalin as a predictor of cardiovascular events in patients with chronic kidney disease. Heart Vessels. 2015; 30 (1): 81–88. doi: 10.1007/s00380-013-0454-7.

63. Lin H. Y., Hwang D. Y., Lee S. C., Kuo H. T., Kuo M. C., Chang J. M. et al. Urinary neutrophil gelatinase-associated lipocalin and clinical outcomes in chronic kidney disease patients. Clin. Chem. Lab. Med. 2015; 53 (1): 73–83. doi: 10.1515/cclm-2014-0647.

64. Bachorzewska-Gajewska H., Tomaszuk-Kazberuk A., Jarocka I., Mlodawska E., Lopatowska P., Zalewska-Adamiec M. et al. Does neutrophil gelatinase-asociated lipocalin have prognostic value in patients with stable angina undergoing elective PCI? A 3-year follow-up study. Kidney Blood Press. Res. 2013; 37 (4–5): 280–285. doi: 10.1159/000350155.

65. Akcay A. B., Ozlu M. F., Sen N., Cay S., Ozturk O. H., Yalcn F. et al. Prognostic significance of neutrophil gelatinaseassociated lipocalin in ST-segment elevation myocardial infarction. J. Investig. Med. 2012; 60 (2): 508–513. doi: 10.231/JIM.0b013e31823e9d86.

66. Foley R. N., Wang C., Collins A. J. Cystatin C, mortality risk and clinical triage in US adults: threshold values and hierarchical importance. Nephrol. Dial. Transplant. 2011; 26 (6): 1831–1837. doi: 10.1093/ndt/gfq629.

67. Shlipak M. G., Matsushita K., Ärnlöv J., Inker L. A., Katz R., Polkinghorne K. R. et al. Cystatin C versus creatinine in determining risk based on kidney function. N. Engl. J. Med. 2013; 369 (10): 932–943. doi: 10.1056/NEJMoa1214234.

68. Luc G., Bard J. M., Lesueur C., Arveiler D., Evans A., Amouyel P. et al. Plasma cystatin-C and development of coronary heart disease: The PRIME Study. Atherosclerosis. 2006; 185 (2): 375–380.

69. Woitas R. P., Kleber M. E., Meinitzer A., Grammer T. B., Silbernagel G., Pilz S. et al. Cystatin C is independently associated with total and cardiovascular mortality in individuals undergoing coronary angiography. The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Atherosclerosis. 2013; 229 (2): 541–548. doi: 10.1016/j.atherosclerosis.2013.04.027.

70. Zang L., Fu P., Liu F., Wu M., Huang Y. Q., Li L. et al. The correlation of serum cystatin C level with the severity of carotid atherosclerosis in patients with type 2 diabetes mellitus. Sichuan. Da. Xue. Xue. Bao. Yi. Xue. Ban. 2012; 43 (6): 882–887.

71. Dandana A., Gammoudi I., Chalghoum A., Chahed H., Addad F., Ferchichi S. et al. Clinical utility of serum cystatin C in predicting coronary artery disease in patients without chronic kidney disease. J. Clin. Lab. Anal. 2014; 28 (3): 191–197. doi: 10.1002/jcla.21665.

72. Negrusz-Kawecka M., Poręba R., Hulok A., Sciborski K., Marczak J., Bańkowski T. Evaluation of the significance of cystatin C levels in patients suffering from coronary artery disease. Adv. Clin. Exp. Med. 2014; 23 (4): 551–558.

73. Lee M., Saver J. L., Huang W. H., Chow J., Chang K. H., Ovbiagele B. Impact of elevated cystatin C level on cardiovascular disease risk in predominantly high cardiovascular risk populations. Circ Cardiovasc. Qual. Outcomes. 2010; 3 (6): 675–683. doi: 10.1161/CIRCOUTCOMES.110.957696.

74. Резниченко Н. Е., Панфилова Е. Ю., Евдокимо­ва М. А., Осмоловская В. С., Чумакова О. С., Данковце­ва Е. Н. и др. Уровень цистатина С независимо связан с риском развития неблагоприятного исхода у лиц, перенесших острый коронарный синдром и имеющих нормальную или незначительно сниженную функцию почек. Кардиология. 2011; 6: 4–11. Reznichenko N. E., Panfilova E. Yu., Evdokimova M. A., Osmolovskaya V. S., Chumakova O. S., Dankovtseva E. N. i dr. Uroven’ tsistatina S nezavisimo svyazan s riskom razvitiya neblagopriyatnogo iskhoda u lits, perenesshikh ostryy koronarnyy sindrom i imeyushchikh normal’nuyu ili neznachitel’no snizhennuyu funktsiyu pochek. Kardiologiya. 2011; 6: 4–11. [In Russ].

75. Silva D., Cortez-Dias N., Jorge C., Marques J. S., Carrilho-Ferreira P., Magalhães A. et al. Cystatin C as prognostic biomarker in ST-segment elevation acute myocardial infarction. Am. J. Cardiol. 2012; 109 (10): 1431–1438. doi: 10.1016/j.amjcard.2012.01.356.

76. Ferraro S., Marano G., Biganzoli E. M., Boracchi P., Bongo A. S. Prognostic value of cystatin C in acute coronary syndromes: enhancer of atherosclerosis and promising therapeutic target. Clin. Chem. Lab. Med. 2011; 49 (9): 1397–1404.

77. Skoglund P. H., Arpegård J., Ostergren J., Svensson P. Amino-terminal pro-B-type natriuretic peptide and high-sensitivity C-reactive protein but not cystatin C predict cardiovascular events in male patients with peripheral artery disease independently of ambulatory pulse pressure. Am. J. Hypertens. 2014; 27 (3): 363–371. doi: 10.1093/ajh/hpt278.

78. Sun T. W., Xu Q. Y., Yao H. M., Zhang X. J., Wu Q., Zhang J. Y. et al. The predictive value of plasma cystatin C for acute coronary syndrome treated with percutaneous coronary intervention. Heart Lung. 2012; 41 (5): 456–462. doi: 10.1016/j.hrtlng.2012.04.007.

79. Skurk T., Kolb H., Müller-Scholze S., Röhrig K., Hauner H., Herder C. The proatherogenic cytokine interleukin-18 issecreted by human adipocytes. Eur. J. Endocrinol. 2005; 152: 863–868.

80. Packard R. R., Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clinical Chemistry. 2008; 54 (1): 24–38.

81. Gerdes N., Sukhova G. K., Libby P., Reynolds R. S., Young J. L., Schonbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J. Exp. Med. 2002; 195: 245–257.

82. Nooijer R., von der Thüsen J. H., Verkleij C. J. N., Kuiper J., Jukema J. W., van der Wall E. E. et al. Overexpression of IL-18 decreases intimal collagen content and promotes a vulnerable plaque phenotype in apolipoprotein-E-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology. 2004; 24: 2313–2319.

83. Badimon L. Interleukin-18: a potent pro-inflammatory cytokine in atherosclerosis. Expert’s perspective. Cardiovasc. Res. 2012; 96 (2): 172–175.

84. Chen M. C., Chen C. J., Yang C. H., Wu C. J., Fang C. Y., Hsieh Y. K. et al. Interleukin-18: a strong predictor of the extent of coronary artery disease in patients with unstable angina. Heart Vessels. 2007; 22 (6): 371–375.

85. Kadoglou N. P., Tahmatzidis D. K., Giannakoulas C., Kapelouzou A., Gkontopoulos A., Parissis J. et al. Serum levels of novel adipokines, omentin-1 and chemerin, in patients with acute myocardial infarction: KOZANI STUDY. J. Cardiovasc. Med. (Hagerstown). 2015; 16 (5): 341–346. doi: 10.2459/JCM.0000000000000053.

86. Koenig W., Khuseyinova N., Baumert J., Thorand B., Loewel H., Chambless L. et al. Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women. Arterioscler. Thromb. Vasc. Biol. 2006; 26 (12): 2745–2751.

87. Rosso R., Roth A., Herz I., Miller H., Keren G., George J. Serum levels of interleukin-18 in patients with stable and unstable angina pectoris. Int. J. Cardiol. 2005; 98: 45–48.

88. Blankenberg S., Luc G., Ducimetiere P., Arveiler D., Ferrieres J., Amouyel P. et al. Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation. 2003; 108: 2453–2459.

89. Zhou J., Deng G., Yang T., Ma Q., Luo X. Association between interleukin-18 and Global Registry of Acute Coronary Events score in patients with acute coronary syndrome. Zhong. Nan. Da. Xue. Xue. Bao. Yi. Xue. Ban. 2014; 39 (6): 570–576. doi: 10.11817/j.issn.1672-7347.2014.06.005.

90. Welsh P., Woodward M., Rumley A., Lowe G. Associations of circulating TNFα and IL-18 with myocardial infarction and cardiovascular risk markers: The Glasgow Myocardial Infarction Study. Cytokine. 2009; 47 (2): 143–147. doi: 10.1016/j.cyto.2009.06.002.

91. Sarnak M. J., Katz R., Newman A., Harris T., Peralta C. A., Devarajan P. et al. Association of urinary injury biomarkers with mortality and cardiovascular events. J. Am. Soc. Nephrol. 2014; 25 (7): 1545–1553. doi: 10.1681/ASN.2013070713.

92. Liu Y., Guo W., Zhang J., Xu C., Yu S., Mao Z. et al. Urinary interleukin 18 for detection of acute kidney injury: a meta-analysis. Am. J. Kidney Dis. 2013; 62 (6): 1058–1067. doi: 10.1053/j.ajkd.2013.05.014.

93. Ghatanatti R., Teli A., Tirkey S. S., Bhattacharya S., Sengupta G., Mondal A. Role of renal biomarkers as predictors of acute kidney injury in cardiac surgery. Asian Cardiovasc. Thorac. Ann. 2014; 22 (2): 234–241. doi: 10.1177/0218492313502028.

94. Хамнуева Л. Ю., Хантакова Е. А., Орлова Г. М. Повышение сывороточного уровня интерлейкина-18 у больных сахарным диабетом 1-го типа. Нефрология и диализ. 2011; 13 (3): 292. Khamnueva L. Yu., Khantakova E. A., Orlova G. M. Povyshenie syvorotochnogo urovnya interleykina-18 u bol’nykh sakharnym diabetom 1-go tipa. Nefrologiya i dializ. 2011; 13 (3): 292. [In Russ].

95. Yong K., Ooi E. M., Dogra G., Mannion M., Boudville N., Chan D. et al. Elevated interleukin-12 and interleukin-18 in chronic kidney disease are not associated with arterial stiffness. Cytokine. 2013; 64 (1): 39–42. doi: 10.1016/j.cyto.2013.05.023.

96. Demova H., Boleckova J., Rose D., Koeppel H., Prochazka B., Brunerova L. et al. Gene polymorphisms in patients with type 2 diabetes and diabetic nephropathy. Central European Journal of Biology. 2012; 7 (2): 210–218.

97. Liebau M. C., Benzing T. Recent developments in genetic kidney diseases. Dtsch. Med. Wochenschr. 2011; 136 (19): 1014–1020. doi: 10.1055/s-0031-1275836.

98. Xue C., Nie W., Tang D., Yi L., Mei C. Apolipoprotein E gene variants on the risk of end stage renal disease. PLoS One. 2013; 8 (12): e83367. doi: 10.1371/journal.pone.0083367.

99. Köttgen A., Pattaro C., Böger C. A., Fuchsberger C., Olden M., Glazer N. L. et al. New loci associated with kidney function and chronic kidney disease. Nat. Genet. 2010; 42 (5): 376–384. doi: 10.1038/ng.568.

100. Campbell C. Y., Fang B. F., Guo X., Peralta C. A., Psaty B. M., Rich S. S. et al. Associations between genetic variants in the ACE, AGT, AGTR1 and AGTR2 genes and renal function in the multi-ethnic study of atherosclerosis. Am. J. Nephrol. 2010; 32 (2): 156–162. doi: 10.1159/000315866.

101. Abdollahi M. R., Huang S., Rodriguez S., Guthrie P. A., Smith G. D., Ebrahim S. et al. Homogeneous assay of rs4343, an ACE I/D proxy, and an analysis in the British Women’s Heart and Health Study (BWHHS). Dis. Markers. 2008; 24 (1): 11–17.

102. Huang S., Chen X. H., Payne J. R., Pennell D. J., Gohlke P., Smith M. J. et al. Haplotype of growth hormone and angiotensin I-converting enzyme genes, serum angiotensin Iconverting enzyme and ventricular growth: pathway inference in pharmacogenetics. Pharmacogenet. Genomics. 2007; 17 (4): 291–294.

103. Kumar A., Vivekanandhan S., Srivastava A., Tripathi M., Padma Srivastava M. V., Saini N. et al. Association between angiotensin converting enzyme gene insertion/deletion polymorphism and ischemic stroke in north Indian population: a case-control study and meta-analysis. Neurol. Res. 2014; 36 (9): 786–794. doi: 10.1179/1743132814Y.0000000335.

104. Moradzadegan A., Vaisi-Raygani A., Nikzamir A., Rahimi Z. Angiotensin converting enzyme insertion/deletion (I/D) (rs4646994) and Vegf polymorphism (+405G/C; rs2010963) in type II diabetic patients: Association with the risk of coronary artery disease. J. Renin Angiotensin Aldosterone Syst. 2014. doi: 10.1177/1470320313497819.

105. Narne P., Ponnaluri K. C., Singh S., Siraj M., Ishaq M. Relationship between angiotensin-converting enzyme gene insertion/deletion polymorphism, angiographically defined coronary artery disease and myocardial infarction in patients with type 2 diabetes mellitus. J. Renin Angiotensin Aldosterone Syst. 2012; 13 (4): 478–486. doi: 10.1177/1470320312448947.

106. Chen Y. H., Liu J. M., Hsu R. J., Hu S. C., Harn H. J., Chen S. P. et al. Angiotensin converting enzyme DD genotype is associated with acute coronary syndrome severity and sudden cardiac death in Taiwan: a case-control emergency room study. BMC Cardiovasc. Disord. 2012; 12: 6. doi:10.1186/1471-2261-12-6.

107. Jia E. Z., Xu Z. X., Guo C. Y., Li L., Gu Y., Zhu T. B., Wang L. S. et al. Renin-angiotensin-aldosterone system gene polymorphisms and coronary artery disease: detection of genegene and gene-environment interactions. Cell Physiol. Biochem. 2012; 29 (3–4): 443–452. doi: 10.1159/000338498.

108. WangF., FangQ., YuN., ZhaoD., ZhangY., Wang J. et al. Association between genetic polymorphism of the angiotensinconverting enzyme and diabetic nephropathy: a meta-analysis comprising 26,580 subjects. J. Renin Angiotensin Aldosterone Syst. 2012; 13 (1): 161–174. doi: 10.1177/1470320311417655.

109. Lin C., Yang H. Y., Wu C. C., Lee H. S., Lin Y. F., Lu K. C. et al. Angiotensin-converting enzyme insertion/deletion polymorphism contributes high risk for chronic kidneydisease in Asian male with hypertension--a meta-regression analysis of 98 observational studies. PLoS One. 2014; 9 (1): e87604. doi: 10.1371/journal.pone.0087604. DOI: 10.1371/journal.pone.0087604.

110. Hamon M., Fradin S., Denizet A., Filippi-Codaccioni E., Grollier G., Morello R. Prospective evaluation of the effect of an angiotensin I converting enzyme gene polymorphism on the long term risk of major adverse cardiac events after percutaneous coronary intervention. Heart. 2003; 89 (3): 321–325.

111. Palmer B. R., Pilbrow A. P., Yandle T. G., Frampton C. M., Richards A. M., Nicholls M. G. et al. Angiotensinconverting enzyme gene polymorphism interacts with left ventricular ejection fraction and brain natriuretic peptide levels to predict mortality after myocardial infarction. J. Am. Coll. Cardiol. 2003; 41 (5): 729–736.

112. Zhu X., Bouzekri N., Southam L., Cooper R. S., Adeyemo A., McKenzie C. A. et al. Linkage and association analysis of angiotensin I-converting enzyme (ACE)-gene polymorphisms with ACE concentration and blood pressure. Am. J. Hum. Genet. 2001; 68: 1139–1148.

113. Keavney B., McKenzie C. A., Connell J. M., Julier C., Ratcliffe P. J., Sobel E. et al. Measured haplotype analysis of the angiotensin-I converting enzyme gene. Hum. Mol. Genet. 1998; 7: 1745–1751.

114. Martínez-Rodríguez N., Posadas-Romero C., Villarreal-Molina T., Vallejo M., Del-Valle-Mondragón L., RamírezBello J. et al. Single nucleotide polymorphisms of the angiotensin-converting enzyme (ACE) gene are associated with essential hypertension and increased ACE enzyme levels in Mexican individuals. PLoS One. 2013; 8 (5): e65700. doi: 10.1371/journal.pone.0065700.

115. Baghai T. C., Binder E. B., Schule C., Salyakina D., Eser D., Lucae S. et al. Polymorphisms in the angiotensin-converting enzyme gene are associated with unipolar depression, ACE activity and hypercortisolism. Mol. Psychiatry. 2006; 11 (11): 1003–1015.

116. Kopple J. D., Massry S. G., Kalantar-Zadeh K. Nutritional Management of Renal Disease. Academic Press (3 edition); 2012. ISBN-13: 978-0123919342.

117. Ariza M. J., Sánchez-Chaparro M. A., Barón F. J., Hornos A. M., Calvo-Bonacho E., Rioja J. et al. Additive effects of LPL, APOA5 and APOE variant combinations on triglyceride levels and hypertriglyceridemia: results of the ICARIA genetic sub-study. BMC Med. Genet. 2010; 11: 66.

118. Hirano T. Lipoprotein abnormalities in diabetic nephropathy. Kidney Int. 199; 71: 22–24.

119. Ayyappa K. A., Ghosh S., Mohan V., Radha V. Association of hepatic lipase gene polymorphisms with hypertriglyceridemia and low high-density lipoprotein-cholesterol levels among South Indian subjects without diabetes. Diabetes Technol. Ther. 2013; 15 (6): 503–512.

120. Ng M. C., Baum L., So W. Y., Lam V. K., Wang Y., Poon E. et al. Association of lipoprotein lipase S447X, apolipoprotein E exon 4, and apoC3 -455T>C polymorphisms on the susceptibility to diabetic nephropathy. Clin. Genet. 2006; 70 (1): 20–28.

121. Алекперов Э. З., Наджаров Р. Н. Современные концепции о роли воспаления при атеросклерозе. Кардиология. 2010; 6: 88–91. Alekperov E. Z., Nadzharov R. N. Sovremennyy kontseptsii o roli vospaleniya pri ateroskleroze. Kardiologiya. 2010; 6: 88–91. [In Russ].

122. Vázquez-Huerta D. I., Alvarez-Rodríguez B. A., Topete-Reyes J. F., Muñoz-Valle J. F., Parra-Michel R., FuentesRamírez F. et al. Tumor necrosis factor alpha -238 G/A and -308 G/A polymorphisms and soluble TNF-α levels in chronic kidney disease: correlation with clinical variables. Int. J. Clin. Exp. Med. 2014; 7 (8): 2111–21119.

123. Ned R. M., Yesupriya A., Imperatore G., Smelser D. T., Moonesinghe R., Chang M. H. et al. The ACE I/D polymorphism in US adults: limited evidence of association with hypertensionrelated traits and sex-specific effects by race/ethnicity. Am. J. Hypertens. 2012; 25 (2): 209–215. doi: 10.1038/ajh.2011.182.

124. Wang Y., Ng M. C., So W. Y., Ma R., Ko G. T., Tong P. C. Association between tumour necrosis factor-alpha G-308A polymorphism and risk of nephropathy in obese Chinese type 2 diabetic patients. Nephrol. Dial. Transplant. 2005; 20: 2733–2738.


Для цитирования:


Зыков М.В. ОСОБЕННОСТИ ТЕЧЕНИЯ И СТРАТИФИКАЦИИ РИСКА ОСЛОЖНЕНИЙ ОСТРОГО КОРОНАРНОГО СИНДРОМА В СОЧЕТАНИИ С ПОЧЕЧНОЙ ДИСФУНКЦИЕЙ И РАЗЛИЧНОЙ СТРАТЕГИЕЙ ЛЕЧЕНИЯ (обзор литературы). Комплексные проблемы сердечно-сосудистых заболеваний. 2015;(3):68-78. https://doi.org/10.17802/2306-1278-2015-3-68-78

For citation:


Zykov M. THE COURSE AND RISK STRATIFICATION OF ACUTE CORONARY SYNDROME IN CONJUNCTION WITH RENAL DYSFUNCTION AND VARIOUS TREATMENT STRATEGIES. Complex Issues of Cardiovascular Diseases. 2015;(3):68-78. (In Russ.) https://doi.org/10.17802/2306-1278-2015-3-68-78

Просмотров: 206


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2306-1278 (Print)
ISSN 2587-9537 (Online)